evolv glp-1 How the Era is driving a Paradigm Shift in Food Industry Growth? Evolv GLP-1 Biomimetic

Regular reviews help optimise dosing, manage side effects, and ensure treatment remains safe and effective for each patients profile

Wegovy (semaglutide) Disease area(s): Metabolic diseases Manufacturer(s): Novo Nordisk 2024 Sales (USD): $8.44 billion Why it sold so well: In 2024, Novo Nordisks obesity products, including Wegovy and Saxenda, achieved significant sales growth, increasing by 56% in Danish kroner to DKK 58.21 billion ($8.44 billion USD)

Dietary supplements are not a substitute for prescription medication or professional care, and they do not replace evaluation or treatment for menopause, including decisions about hormone therapy

This means the current duopoly between Eli Lilly and Novo Nordisk could start to be diluted, potentially leading to more competition in the market

Please note that compounded medications are customized to meet individual patient needs and are not FDA-approved for safety or effectiveness